Jeffrey Hermanson is a corporate lawyer whose practice focused on representing public and private companies in all aspects of mergers and acquisitions. He provides guidance, develops and implements business-focused strategies, and handles numerous complex transactions for a variety of clients, particularly those in the life sciences and technology sectors. Mr. Hermanson advises on numerous divisional transactions, and acquisitions and dispositions of public and private companies.


Recent Highlights

Representation of:

  • The Medicines Company in its acquisition of Incline Therapeutics
  • Acorda Therapeutics in its acquisition of Neuronex, Inc.
  • Nabriva Therapeutics in its transaction with Forest Laboratories
  • Prism Pharmaceuticals, Inc. in its sale to Baxter Healthcare Corporation
  • Akamai Technologies, Inc. in its acquisition of Verivue, Inc.
  • SkillSoft plc in its acquisition of Thomson Learning's NETg Business
  • GloNav Inc. in its sale to NXP Semiconductors
  • Parexel in its acquisition of APEX International Clinical Research
  • Alnylam Pharmaceuticals in the sale of its German operations to Roche
  • GlycoFi Inc. in its sale to Merck & Co., Inc.
  • Xanthus Inc. in its sale to Antisoma Research Limited
  • Intercontinental Real Estate in its acquisition of Marine Lumber Company
  • Nationwide Health Properties in its acquisition of Epoch Senior Living
  • Rolls Royce Naval Marine in its acquisition of Seaworthy Systems, Inc.
  • Berkshire Mortgage Finance in its acquisition by Deutsche Bank


Honors & Awards

  • LMG Life Sciences selected the firm as winner of its “Canadian Impact Deals of the Year” in 2013 award for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.

Insights & News


  • Education

    • JD, Boston University School of Law, 1984

      cum laude
    • BA, Colby College, 1981

      magna cum laude Phi Beta Kappa
  • Admissions

    • Massachusetts



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.